Targeting Apoptosis in AML: Where Do We Stand?

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Over 97% of acute myeloid leukemia (AML) patients exhibit genetic mutations driving excessive cell proliferation.
• Evasion of regulated cell death (RCD), particularly apoptosis, is a hallmark of cancer, contributing to AML development and drug resistance.
• The balance of BCL-2 family proteins critically regulates apoptosis and cell survival.

Purpose of the Study:

• To provide a comprehensive review of current and future acute myeloid leukemia (AML) treatment strategies.
• To highlight the role of apoptosis, especially the mitochondrial pathway, in AML pathogenesis and therapy.
• To explore emerging therapeutic concepts like neddylation in AML treatment.

Main Methods:

• Literature review of current AML treatment options.
• Analysis of the molecular mechanisms of apoptosis and its regulation in AML.
• Examination of the clinical relevance of apoptosis-targeting therapies.

Main Results:

• Apoptosis evasion is central to AML progression and therapeutic resistance.
• Targeting the BCL-2 protein family and the mitochondrial apoptosis pathway presents viable therapeutic strategies.
• Neddylation is an emerging area with potential therapeutic implications for AML.

Conclusions:

• Understanding apoptosis mechanisms is crucial for developing effective AML therapies.
• Targeted therapies focusing on apoptosis regulation offer significant promise for AML treatment.
• Future AML treatment will likely involve a combination of apoptosis-modulating agents and novel strategies like neddylation inhibition.